ARL6IP5 and breast carcinoma: JWA inhibits the expression of Cyclin-dependent kinase 12 (CDK12), which participates in the transition from G1 to S phase, thus suppressing the proliferation of trastuzumab-resistant breast cancer cells, and promoting their apoptosis [24].